A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/18 (2006.01) A61K 39/395 (2006.01) A61P 3/10 (2006.01) C07K 16/32 (2006.01)
Patent
CA 2368017
The invention provides methods for treating pancreatic dysfunction, particularly diabetes, in mammals using ErbB receptor ligands, such as heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such therapeutically useful agents to mammals, or alternatively, by exposing certain pancreatic cell types to such agents in vitro and subsequently transplanting the treated cells to a mammal.
Cette invention concerne des méthodes de traitement du dysfonctionnement pancréatique, en particulier du diabète, chez les mammifères, au moyen de ligands récepteurs ErbB, tels que l'heréguline,la bétacelluline et EGF. L'invention concerne également des méthodes de traitement de ces pathologies au moyen d'anticorps agonistes anti-récepteur ErbB. Selon l'invention, on peut administrer directement ces agents utiles au plan thérapeutique à des mammifère, ou, en variante, exposer certains types de cellules pancréatiques à de tels agents in vitro et transplanter ultérieurement les cellules traitées dans un mammifères.
Huang Xiaojian
Stewart Timothy Andrew
Genentech Inc.
Smart & Biggar
LandOfFree
Use of erbb receptor ligands in treating diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of erbb receptor ligands in treating diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of erbb receptor ligands in treating diabetes will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1662726